BioNexus Gene Lab Corp. Common Stock, Capital Shares Reserved for Future Issuance
BioNexus Gene Lab Corp. (BGLC) had Common Stock, Capital Shares Reserved for Future Issuance of 593.63 thousand shares as of 2026-01-01, per its 10-Q filed 2026-08-14.
Financial Statements › Notes
us-gaap:CommonStockCapitalSharesReservedForFutureIssuance · last filed 2026-08-14
- 2026-01-01: Common Stock, Capital Shares Reserved for Future Issuance 593.63K shares.
| Period end | Common Stock, Capital Shares Reserved for Future Issuance |
|---|---|
| 2026-01-01 | 593.63K shares 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |